In Vitro and In Vivo Effects of Melatonin-Containing Combinations in Human Pancreatic Ductal Adenocarcinoma.
Melatonin
/ pharmacology
Carcinoma, Pancreatic Ductal
/ drug therapy
Humans
Animals
Pancreatic Neoplasms
/ drug therapy
Mice
Cell Line, Tumor
Gemcitabine
Cannabidiol
/ pharmacology
Deoxycytidine
/ analogs & derivatives
Cell Proliferation
/ drug effects
Xenograft Model Antitumor Assays
Cell Survival
/ drug effects
cannabidiol
integrative therapy
melatonin
oxygen–ozone therapy
pancreatic cancer
Journal
Journal of pineal research
ISSN: 1600-079X
Titre abrégé: J Pineal Res
Pays: England
ID NLM: 8504412
Informations de publication
Date de publication:
Aug 2024
Aug 2024
Historique:
revised:
20
06
2024
received:
24
02
2024
accepted:
17
07
2024
medline:
30
7
2024
pubmed:
30
7
2024
entrez:
30
7
2024
Statut:
ppublish
Résumé
Pancreatic ductal adenocarcinoma (PDAC) has poor prognosis and high mortality rates. Therefore, it is necessary to identify new targets and therapeutic strategies to improve the prognosis of patients with PDAC. Integrative therapies are increasingly being used to boost the efficacy of the known anticancer therapeutic approaches. Hence, this study aimed to evaluate the effects of a novel combination of different potential anticancer molecules, melatonin (MLT), cannabidiol (CBD), and oxygen-ozone (O
Substances chimiques
Melatonin
JL5DK93RCL
Gemcitabine
0
Cannabidiol
19GBJ60SN5
Deoxycytidine
0W860991D6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e12997Subventions
Organisme : The work was co-financed by Fondazione Maria Guarino Amor ETS.
Informations de copyright
© 2024 The Author(s). Journal of Pineal Research published by John Wiley & Sons Ltd.
Références
A. J. Grossberg, L. C. Chu, C. R. Deig, et al., “Multidisciplinary Standards of Care and Recent Progress in Pancreatic Ductal Adenocarcinoma,” CA: A Cancer Journal for Clinicians 70, no. 5 (2020): 375–403, https://doi.org/10.3322/caac.21626.
H. A. Burris, M. J. Moore, J. Andersen, et al., “Improvements in Survival and Clinical Benefit With Gemcitabine as First‐Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial,” Journal of Clinical Oncology 41, no. 36 (2023): 5482–5492, https://doi.org/10.1200/JCO.22.02777.
Y. J. Yi, H. Tang, P. L. Pi, et al., “Melatonin in Cancer Biology: Pathways, Derivatives, and the Promise of Targeted Delivery,” Drug Metabolism Reviews 56, no. 1 (2024): 62–79, https://doi.org/10.1080/03602532.2024.2305764.
A. Lozano, J. Marruecos, J. Rubió, et al., “Randomized Placebo‐Controlled Phase II Trial of High‐Dose Melatonin Mucoadhesive Oral Gel for the Prevention and Treatment of Oral Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy Concurrent With Systemic Treatment,” Clinical and Translational Oncology 23 (2021): 1801–1810, https://doi.org/10.1007/s12094-021-02586.
M. Li, B. Hao, M. Zhang, et al., “Melatonin Enhances Radiofrequency‐Induced NK Antitumor Immunity, Causing Cancer Metabolism Reprogramming and Inhibition of Multiple Pulmonary Tumor Development,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 330, https://doi.org/10.1038/s41392-021-00745-7.
A. C. S. Palmer, M. Zortea, A. Souza, et al., “Clinical Impact of Melatonin on Breast Cancer Patients Undergoing Chemotherapy; Effects on Cognition, Sleep and Depressive Symptoms: A Randomized, Double‐Blind, Placebo‐Controlled Trial,” PLoS One 15, no. 4 (2020): e0231379, https://doi.org/10.1371/journal.pone.0231379.
H. Q. Ju, H. Li, T. Tian, et al., “Melatonin Overcomes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma by Abrogating Nuclear Factor‐κB Activation,” Journal of Pineal Research 60, no. 1 (2016): 27–38, https://doi.org/10.1111/jpi.12285.
Z. Fang, K. H. Jung, H. H. Yan, et al., “Melatonin Synergizes With Sorafenib to Suppress Pancreatic Cancer via Melatonin Receptor and PDGFR‐β/STAT3 Pathway,” Cellular Physiology and Biochemistry 47, no. 5 (2018): 1751–1768, https://doi.org/10.1159/000491058.
Y. Chan, H. Tan, Y. Lu, et al., “Pancreatic Melatonin Enhances Anti‐Tumor Immunity in Pancreatic Adenocarcinoma Through Regulating Tumor‐Associated Neutrophils Infiltration and NETosis,” Acta Pharmaceutica Sinica B 13, no. 4 (2023): 1554–1567, https://doi.org/10.1016/j.apsb.2023.01.020.
C. Xu, A. Wu, H. Zhu, et al., “Melatonin Is Involved in the Apoptosis and Necrosis of Pancreatic Cancer Cell Line SW‐1990 via Modulating of Bcl‐2/Bax Balance,” Biomedicine & Pharmacotherapy 67, no. 2 (2013): 133–139, https://doi.org/10.1016/j.biopha.2012.10.005.
O. R. Tamtaji, N. Mirhosseini, R. J. Reiter, M. Behnamfar, and Z. Asemi, “Melatonin and Pancreatic Cancer: Current Knowledge and Future Perspectives,” Journal of Cellular Physiology 234, no. 5 (2019): 5372–5378, https://doi.org/10.1002/jcp.27372.
V. Cherkasova, B. Wang, M. Gerasymchuk, A. Fiselier, O. Kovalchuk, and I. Kovalchuk, “Use of Cannabis and Cannabinoids for Treatment of Cancer,” Cancers 14, no. 20 (2022): 5142, https://doi.org/10.3390/cancers14205142.
C. Twelves, M. Sabel, D. Checketts, et al., “A Phase 1b Randomised, Placebo‐Controlled Trial of Nabiximols Cannabinoid Oromucosal Spray With Temozolomide in Patients With Recurrent Glioblastoma,” British Journal of Cancer 124, no. 8 (2021): 1379–1387, https://doi.org/10.1038/s41416-021-01259-3.
D. Bhaskaran, J. Savage, A. Patel, et al., “A Randomised Phase II Trial of Temozolomide With or Without Cannabinoids in Patients With Recurrent Glioblastoma (ARISTOCRAT): Protocol for a Multi‐Centre, Double‐Blind, Placebo‐Controlled Trial,” BMC Cancer 24, no. 1 (2024): 83, https://doi.org/10.1186/s12885-023-11792-4.
J. Schloss, J. Lacey, J. Sinclair, et al., “A Phase 2 Randomised Clinical Trial Assessing the Tolerability of Two Different Ratios of Medicinal Cannabis in Patients With High Grade Gliomas,” Frontiers in Oncology 11 (2021): 649555, https://doi.org/10.3389/fonc.2021.649555.
R. Ferro, A. Adamska, R. Lattanzio, et al., “GPR55 Signalling Promotes Proliferation of Pancreatic Cancer Cells and Tumour Growth in Mice, and Its Inhibition Increases Effects of Gemcitabine,” Oncogene 37, no. 49 (2018): 6368–6382, https://doi.org/10.1038/s41388-018-0390-1.
M. Luongo, O. Marinelli, L. Zeppa, et al., “Cannabidiol and Oxygen‐Ozone Combination Induce Cytotoxicity in Human Pancreatic Ductal Adenocarcinoma Cell Lines,” Cancers 12, no. 10 (2020): 2774, https://doi.org/10.3390/cancers12102774.
M. E. G. Serra, J. Baeza‐Noci, C. V. Mendes Abdala, M. M. Luvisotto, C. D. Bertol, and A. P. Anzolin, “The Role of Ozone Treatment as Integrative Medicine. An Evidence and Gap Map,” Frontiers in Public Health 10 (2023): 1112296, https://doi.org/10.3389/fpubh.2022.1112296.
B. Clavo, G. Martínez‐Sánchez, F. Rodríguez‐Esparragón, et al., “Modulation by Ozone Therapy of Oxidative Stress in Chemotherapy‐Induced Peripheral Neuropathy: The Background for a Randomized Clinical Trial,” International Journal of Molecular Sciences 22, no. 6 (2021): 2802, https://doi.org/10.3390/ijms22062802.
F. Sweet, M. S. Kao, S. C. Lee, W. L. Hagar, and W. E. Sweet, “Ozone Selectively Inhibits Growth of Human Cancer Cells,” Science 209, no. 4459 (1980): 931–933, https://doi.org/10.1126/science.7403859.
M. Luongo, A. L. Brigida, L. Mascolo, and G. Gaudino, “Possible Therapeutic Effects of Ozone Mixture on Hypoxia in Tumor Development,” Anticancer Research 37, no. 2 (2017): 425–436, https://doi.org/10.21873/anticanres.11334.
B. Clavo, N. Santana‐Rodríguez, P. Llontop, et al., “Ozone Therapy as Adjuvant for Cancer Treatment: Is Further Research Warranted?” Evidence‐Based Complementary and Alternative Medicine 2018 (2018): 7931849, https://doi.org/10.1155/2018/7931849.
A. Ianevski, A. K. Giri, and T. Aittokallio, “SynergyFinder 3.0: An Interactive Analysis and Consensus Interpretation of Multi‐Drug Synergies Across Multiple Samples,” Nucleic Acids Research 50, no. W1 (2022): W739–W743, https://doi.org/10.1093/nar/gkac382.
L. K. Godfrey, J. Forster, S. T. Liffers, et al., “Pancreatic Cancer Acquires Resistance to MAPK Pathway Inhibition by Clonal Expansion and Adaptive DNA Hypermethylation,” Clinical Epigenetics 16, no. 1 (2024): 13, https://doi.org/10.1186/s13148-024-01623-z.